Pancreatic cancer and cholangiocarcinoma are the most aggressive cancer types with dismal prognosis. New combination chemotherapy, such as nab-paclitaxal plus gemcitabine, FOLFIRINOX for pancreatic cancer and cisplatin plus gemcitabine for cholangiocarcinoma, have improved progression-free survival and overall survival in patients with unresectable locally advanced or metastatic cancer. However, it is often difficult to distinguish pancreatic head cancer from distal cholangiocarcinoma, because of their histological and anatomical similarity. This study aims to identify novel protein biomarkers to distinguish these lethal cancers, using proteomic analysis of laser micro-dissected (LMD) formalin-fixed paraffin embedded tissue (FFPE).
Ten cases of pancreatic head cancer and 8 of distal cholangiocarcinoma were analyzed. Cancerous cells collected from FFPE tissue sections by LMD were processed for liquid chromatography tandem MS (LC-MS/MS). Candidate proteins were identified by semi-quantitative comparison so-called spectral counting analysis and also chosen based on the nonparametric G-test with statistical significance as indicated by p
Consequently, 1,361 proteins were detected in pancreatic head cancer and 1,274 proteins in distal cholangiocarcinoma. In total, 1,820 proteins were detected from 18 samples. The detected proteins were semi-quantitatively compared and statistically analyzed by G-test with a significant difference. We identified 6 proteins were overexpressed in pancreatic head cancer groups and 12 proteins in distal cholangiocarcinoma groups, respectively.
We identified 18 candidate protein biomarkers for distinguishing pancreatic head cancer from distal cholangiocarcinoma using proteomic analysis.
Clinical trial indentification
Legal entity responsible for the study
Japan Society for the Promotion of Science
All authors have declared no conflicts of interest.